Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
Buckling precious cargo into a late-model vehicle has gotten a bit easier in the past year, the Institute’s LATCH ease-of-use ratings show.
IIHS launched its ratings of child seat installation hardware in vehicles in June 2015. Out of 102 vehicles rated at that time, the majority were poor or marginal. Today, a total of 170 current models have been evaluated, and most are good or acceptable. Three models — the Audi Q7, Lexus RX and Toyota Prius — earn the top rating of good+, a distinction that no vehicle achieved last year.
A properly installed, age-appropriate child restraint can protect a child much better in a crash than a safety belt alone. LATCH, which stands for Lower Anchors and Tethers for Children, is intended to make it easier for caregivers to install child restraints properly. Child restraints installed with LATCH are more likely to be put in correctly than restraints installed using the vehicle safety belt, IIHS research has shown.
Even with LATCH, installation errors are common. The Institute’s ratings are based on key ease-of-use criteria that have been shown to minimize mistakes.
Last night Sandvik Coromant, a global leading supplier of cutting edge tools, tooling solutions and know-how to the metalworking industry, lit up the Chicago skyline with insightful images designed to spread the word about the profound impact data and technology has on the manufacturing industry and people’s daily lives. The display also included inspirational images depicting the future of digital manufacturing created by Samuel and Erika Flickinger, a brother and sister from Decatur, IL. The two students, who participated in STEM education “Dream It. Do It.” summer camps created by The Manufacturing Institute, literally helped ‘flip the switch’ on the light show and also each received a $1,000 check toward their future education.
“Our goal with this light show was to raise awareness about the amazing opportunities that the use of data is driving in the manufacturing industry and honor two very creative students,” said Sean Holt, President Sandvik Coromant Americas. “We are proud to help raise awareness about the present and future opportunities of digital manufacturing, including the skilled and high paying career options for future generations.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7833454-sandvik-coromant-manufacturing-technology-show/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Holland America Line turns its culinary programming up a notch with the introduction of dynamic shipboard cooking shows produced in partnership with the long-running public television show America’s Test Kitchen, the most popular how-to-cook show on TV. Holland America Line is a sponsor of America’s Test Kitchen on public television, and is proud to make this experience possible at sea. The initiative was announced today in New York City at a press conference at the prestigious Institute of Culinary Education.
Holland America Line’s shipboard Culinary Arts Center will be transformed to replicate the television set where the prominent America’s Test Kitchen TV shows are recorded for broadcast by more than 350 public television stations nationwide. Designed specifically for Holland America Line, the shipboard shows will be hosted by Holland America Line chefs trained by America’s Test Kitchen culinary experts. Shipboard cooking demonstrations and hands-on workshops — with topics ranging from shaping Asian dumplings to making the perfect pie crust — will combine foolproof, accessible recipes and cooking techniques that are rooted in the rigorous testing and science-based approach of America’s Test Kitchen.
To view the multimedia release go to:
http://www.multivu.com/players/English/7363858-americas-test-kitchen-joins-holland-america/
Barcelona is hosting the third edition of the Wine & Culinary International Forum today, a biennial international conference dedicated to food and wine pairing promoted by Bodegas Torres. Over 250 professionals, including sommeliers, restaurant owners, distributors and journalists from almost 20 different countries, participated in the event. Celebrated in the Palau de Congressos de Catalunya, it provided a forum in which to reflect and discuss the complementary relationship between wine and food under the heading “Wine and World Cuisines.”
The president of Bodegas Torres, Miguel A. Torres, opened the event, which featured talks, tastings and culinary demonstrations by a total of 20 national and international experts who are highly regarded in their fields. Among them, Josep Roca, sommelier at El Celler de Can Roca; the award winning wine-writer and journalist Sarah Jane Evans MW, an expert in Spanish wines as well as the former Chairman of the Institute of Masters of Wine; the prestigious French enologist Pascal Chatonnet, one of the leading researchers into the microbiological factors involved in the interaction between wine and oak; Canadian researcher François Chartier, a pioneer in the aromatic science of molecular food matching since 2004 and author of Taste Buds and Molecules, world’s best innovative food 2010; the renowned French wine critic Michel Bettane; and the endocrinologist Dr. Francisco Tinahones, a researcher at the University of Malaga.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7948051-torres-wine-culinary-international-forum/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
WebMD and Scripps Translational Science Institute (STSI) today announced a new investigative study designed to improve researchers’ and health care professionals’ understanding of what contributes to healthy pregnancies and positive pregnancy outcomes. The Healthy Pregnancy Study will use WebMD’s newly redesigned and enhanced Pregnancy app for iPhone. Incorporation of the Apple ResearchKit software framework will enable survey participants to eConsent, easily and anonymously answer questions, and share connected device data about their pregnancies with researchers for analysis.
“Pregnant women are one of the least studied populations in medical research,” said Dr. Eric Topol, director of STSI and editor-in-chief of Medscape. “The results of our Healthy Pregnancy Study -- on the foundation of an exceptionally popular smartphone app -- will ultimately provide expectant mothers, researchers, and health care professionals with new medical insights to avoid complications during pregnancy.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7579757-webmd-stsi-healthy-pregnancy-study-app/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8150951-23andme-genetic-study-depression-bipolar-disorders/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
Four-time PGA TOUR winner Tim Herron is teaming up with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), Damon Adamany, MD, of The CORE Institute and the Facts on Hand campaign to educate adults about one of the more common hand conditions. The campaign is raising awareness of Dupuytren’s Contracture, a progressive, potentially disfiguring hand condition affecting a layer of tissue underneath the palms that can cause one or more fingers to move into a bent position so they cannot be straightened.
Dupuytren’s Contracture, sometimes referred to as “Viking Disease,” can make everyday tasks difficult, such as grabbing an object at home, or in Tim Herron’s case, a nine iron from his golf bag. Many people live with the disease without being diagnosed because they mistakenly assume they have arthritis or another hand condition. And because Dupuytren’s Contracture may progress slowly, people may not pay attention to it until they can no longer straighten their fingers, complicating everyday activities.
To view the multimedia release go to:
https://www.multivu.com/players/English/8153851-endo-facts-on-hand-dupuytrens-contracture/
